GT200000180A - Cristales de inhibidor del intercambiador de sodio - hidrogeno. - Google Patents

Cristales de inhibidor del intercambiador de sodio - hidrogeno.

Info

Publication number
GT200000180A
GT200000180A GT200000180A GT200000180A GT200000180A GT 200000180 A GT200000180 A GT 200000180A GT 200000180 A GT200000180 A GT 200000180A GT 200000180 A GT200000180 A GT 200000180A GT 200000180 A GT200000180 A GT 200000180A
Authority
GT
Guatemala
Prior art keywords
crystals
nhe1
inhibiting
proliferation
cells
Prior art date
Application number
GT200000180A
Other languages
English (en)
Inventor
Lyle Robinson Brostrom
Terrence Joseph Connolly
Zheng Jane Li
Susan Lee Orrill
Bharat Kiritkumar Shah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200000180A publication Critical patent/GT200000180A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

CRISTALES INHIBIDORES DEL NHE1, LOS PROCEDIMIENTOS DE USO DE TALES CRISTALES INHIBIDORES DEL NHE1 Y COMPOSICIONES FARMACEUTICAS QUE CONTIENEN TALES CRISTALES INIBIDORES DEL NHE1. LOS CRISTALES DE TALES INHIBIDORES DEL NHE1 SON UTILES PARA REDUCIR LA LESION EN LOS TEJIDOS ORIGINADA POR UNA ISQUEMIA EN LOS TEJIDOS. LOS CRISTALES DE ESTA INVENCION SE PUEDEN USAR COMO AGENTES PARA LA PROTECCION DEL MIOCARDIO ANTES, DURANTE O DESPUES DE CIRUGIAS DE INJERTO CON DESVIACION DE LA ARTERIA CORONARIA (CABG), CIRUGIAS VASCULARES, ANGIOPLATIA CORONARIA PERCUTANEA TRANSLUMINAL (PTCA), TRASPLANTE DE ORGANOS O CIRUGIAS NO CARDIACAS. ADEMAS, LOS CRISTALES DE ESTA INVENCION SON NOTABLES POR SU POTENTE EFECTO INHIBIDOR DE LA PROLIFERACION DE CELULAS, POR EJEMPLO, LA PROLIFERACION DE CELULAS DE FIBROBLASTO Y LA PROLIFERACION DE CELULAS DEL MUSCULO LISO DE LOS VASOS SANGUINEOS.
GT200000180A 1999-10-29 2000-10-18 Cristales de inhibidor del intercambiador de sodio - hidrogeno. GT200000180A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29

Publications (1)

Publication Number Publication Date
GT200000180A true GT200000180A (es) 2002-04-11

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200000180A GT200000180A (es) 1999-10-29 2000-10-18 Cristales de inhibidor del intercambiador de sodio - hidrogeno.

Country Status (44)

Country Link
EP (1) EP1224179B1 (es)
JP (1) JP2003512455A (es)
KR (1) KR100464526B1 (es)
CN (2) CN1636991A (es)
AP (1) AP2002002493A0 (es)
AR (1) AR029402A1 (es)
AT (1) ATE271047T1 (es)
AU (1) AU778573B2 (es)
BG (1) BG106729A (es)
BR (1) BR0015275A (es)
CA (1) CA2389020A1 (es)
CO (1) CO5271714A1 (es)
CZ (1) CZ20021332A3 (es)
DE (1) DE60012208T2 (es)
DK (1) DK1224179T3 (es)
DZ (1) DZ3463A1 (es)
EA (1) EA004937B1 (es)
EE (1) EE200200227A (es)
ES (1) ES2222923T3 (es)
GE (1) GEP20043222B (es)
GT (1) GT200000180A (es)
HK (1) HK1048472B (es)
HR (1) HRP20020366B1 (es)
HU (1) HUP0204009A3 (es)
IL (1) IL148581A0 (es)
IS (1) IS6302A (es)
MA (1) MA26840A1 (es)
MX (1) MXPA02004358A (es)
NO (1) NO20021821D0 (es)
NZ (1) NZ517738A (es)
OA (1) OA12080A (es)
PA (1) PA8505501A1 (es)
PE (1) PE20010764A1 (es)
PL (1) PL354869A1 (es)
PT (1) PT1224179E (es)
SI (1) SI1224179T1 (es)
SK (1) SK5312002A3 (es)
SV (1) SV2002000209A (es)
TN (1) TNSN00210A1 (es)
TR (1) TR200201167T2 (es)
UA (1) UA72002C2 (es)
WO (1) WO2001030759A2 (es)
YU (1) YU31502A (es)
ZA (1) ZA200203295B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
WO2002060892A1 (en) * 2001-01-31 2002-08-08 Pfizer Products Inc. Ethanolates of sodium-hydrogen exchanger type-1 inhibitor
MXPA04006615A (es) * 2002-01-30 2004-10-04 Pfizer Prod Inc Composiciones farmaceuticas de mesilato de zoniporida y procedimientos para mejorar la solubilidad de la zoniporida.
EP1499317A1 (en) * 2002-05-02 2005-01-26 Pfizer Products Inc. Treatment of diabetes and diabetic complications with nhe-1 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9908332A (pt) * 1998-02-27 2000-11-07 Pfizer Prod Inc Derivados de n-[carbonil(anel di ou triaza diinsaturado de cinco membros substituìdo)] derivados de guanidina para tratamento de esquemia

Also Published As

Publication number Publication date
HK1048472B (zh) 2005-09-16
NO20021821L (no) 2002-04-18
AU778573B2 (en) 2004-12-09
AU7441500A (en) 2001-05-08
PT1224179E (pt) 2004-10-29
YU31502A (sh) 2004-12-31
MA26840A1 (fr) 2004-12-20
AP2002002493A0 (en) 2002-06-30
MXPA02004358A (es) 2002-11-07
ES2222923T3 (es) 2005-02-16
EE200200227A (et) 2003-06-16
EP1224179A2 (en) 2002-07-24
NO20021821D0 (no) 2002-04-18
GEP20043222B (en) 2004-04-26
EP1224179B1 (en) 2004-07-14
CO5271714A1 (es) 2003-04-30
HRP20020366B1 (en) 2005-04-30
DE60012208D1 (de) 2004-08-19
SV2002000209A (es) 2002-07-16
SK5312002A3 (en) 2003-01-09
BG106729A (bg) 2002-12-29
CN1384829A (zh) 2002-12-11
OA12080A (en) 2003-08-25
DK1224179T3 (da) 2004-10-25
EA004937B1 (ru) 2004-10-28
KR20020040918A (ko) 2002-05-30
TNSN00210A1 (fr) 2005-11-10
IS6302A (is) 2002-03-15
CZ20021332A3 (cs) 2002-10-16
HUP0204009A3 (en) 2004-07-28
HRP20020366A2 (en) 2004-02-29
CN1205205C (zh) 2005-06-08
PL354869A1 (en) 2004-03-08
EA200200416A1 (ru) 2002-10-31
JP2003512455A (ja) 2003-04-02
PE20010764A1 (es) 2001-07-23
CN1636991A (zh) 2005-07-13
NZ517738A (en) 2005-06-24
WO2001030759A2 (en) 2001-05-03
HK1048472A1 (en) 2003-04-04
AR029402A1 (es) 2003-06-25
SI1224179T1 (en) 2004-10-31
HUP0204009A2 (hu) 2003-03-28
BR0015275A (pt) 2002-07-16
UA72002C2 (en) 2005-01-17
DZ3463A1 (fr) 2001-05-03
KR100464526B1 (ko) 2005-01-03
PA8505501A1 (es) 2003-09-05
WO2001030759A3 (en) 2001-09-13
ZA200203295B (en) 2003-06-25
TR200201167T2 (tr) 2002-08-21
CA2389020A1 (en) 2001-05-03
DE60012208T2 (de) 2005-07-21
ATE271047T1 (de) 2004-07-15
IL148581A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
PA8557101A1 (es) Benzimidazoles
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
SV1995000002A (es) Uso y obtencion de derivados tetraciclicos ref. 1233cv/vs
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
AR024138A1 (es) Inhibidores de la proliferacion celular
BR0015605A (pt) Composição e uso
ES2175741T3 (es) Nuevos derivados del acido sulfinico, su procedimiento de preparacion y su utilizacion.
ECSP045407A (es) Benzazoles sustituidos y el uso del mismo como inhibidores de quinasa raf
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
AR031430A1 (es) Compuestos de bisarilo orto, meta-sustituidos, procedimientos para su preparacion, su utilizacion como medicamento como tambien los preparados farmaceuticos que los contienen
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
AR056586A1 (es) Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
GT200600294A (es) Mezclas fungicidas a base de bifenilamidas de ácido pirazolcarboxílico 3-monosustituidas
AR025078A1 (es) Utilizacion de agentes antagonistas del cgrp e inhibidores de la liberacion del cgrp para combatir sofocos menopausicos
ECSP045138A (es) 4-Fenil-tetrahidro-isoquinolinas sustituídas, procedimiento para su preparación, su uso como medicamento y medicamento que las contiene
AR010050A1 (es) COMPUESTO TRICíCLICO SUSTITUIDO, COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE Y USO PARA FABRICAR UN MEDICAMENTO PARA INHIBIR SELECTIVAMENTE SPLA2
ES2095662T3 (es) Derivados de imidazol con actividad antagonista de la angiotensina ii.
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
GT200000180A (es) Cristales de inhibidor del intercambiador de sodio - hidrogeno.
MX9301157A (es) Derivados de bencimidazolona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ECSP055673A (es) Derivados de 4-(3,5-dicianofenoxi) pirazol para el uso como moduladores de transcriptasa reversa en el tratamiento del vih